Vitamin D₃ supplementation on plasma antioxidant enzymes in D₃ deficient patients with COPD - a randomized controlled trial

Abstract

Background: Free radical is a crucial factor for progression of COPD. Antioxidant enzymes, including superoxide dismutase (SOD) and catalase (CAT) have been well known to reduce morbidity of chronic disease. Vitamin D3 has antioxidant effect in human body.
 Objectives: To assess the effects of D3 supplementation on plasma SOD and CAT levels in D3 deficient COPD patients.
 Method: A double blinded placebo controlled randomized clinical trial was carried out on 30 vitamin D3 deficient male, smoker and stable COPD patients of age >40 years. All the patients were randomly allocated to ‘Study’ (n=15) or ‘Control’ (n=15) and their baseline plasma SOD and CAT were measured. Study patients received 80,000 IU (2 oral capsules) of D3 per week for first 13 weeks. Subsequently, after checking their serum 25(OH)D or Ca2+, they received 40,000 IU (1 oral capsule) of D3 either per 1 week or per 2 weeks or per 6 weeks or no further supplementation for next 13 weeks. All the ‘Control’ patients received two oral capsules of placebo weekly for consecutive 26 weeks. Additionally, all patients of both groups were also advised to have sunlight exposure (within 11 to 14 hrs) at least for 5 to 15 minutes daily. After 26 weeks of follow up, both enzymes, serum 25(OH)D or Ca2+of all patients were measured by spectrophotometry. Data were analyzed by paired sample and independent sample ‘t’ test.
 Results: The baseline plasma SOD (14.80±3.86U/ml vs 11.95±4.03U/ml) and CAT (11.0±7.59U/ml vs14.41±4.83U/ml) in study and control was almost similar (p>0.05). However, the mean SOD (18.98±2.98U/ml) and CAT (32.75±9.70U/ml) significantly increased (p<0.01; p<0.001) after 26 weeks of follow up only in ‘Study’ patients. In addition, both enzymes were significantly (p<0.001) higher in the D3 supplemented patients than those of placebo treated patients after 26 weeks of follow up.
 Conclusion: The present study reveals that vitamin D3 supplementation increases the plasma antioxidant enzymes in D3 deficient patients with COPD.
 Trial registration: www.clinicaltrials.gov identifier NCT04011930
 J Bangladesh Soc Physiol. 2020, June; 15(1): 23-32

A Comprehensive Review on Vitamin D as a Novel Therapeutic Agent in Chronic Obstructive Pulmonary Disease

“…Ghodrati et al performed a clinical trial and found out the curative role of this vitamin in treating dyspnea in COPD patients [44]. Supplementation can seemingly reduce the progression and morbidity of chronic diseases by decreasing the number of free radicals with antioxidant enzymes, as observed in the latest randomized control trial performed in Bangladesh by Anjum et al [45]. PRECOVID and Lung VITAL are two large ongoing clinical trials with registration numbers NCT02122627 and NCT01728571, respectively.…”